Request Demo
Last update 24 May 2025
KK-2260
Last update 24 May 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms KK-2260 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), TfR1 antagonists(Transferrin receptor protein 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with KK-2260JPRN-jRCT2031230372
A Phase 1, uncontrolled, open-label, non-randomized, dose-escalation study of KK2260 in patients with advanced or metastatic solid tumors, followed by an uncontrolled, randomized study in patients with esophageal cancer or head and neck squamous cell carcinoma
NCT06248411
A Phase 1, Uncontrolled, Open-label, Non-randomized, Dose-escalation Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors, Followed by an Uncontrolled, Non-randomized Study and an Uncontrolled, Randomized Study in Patients With Esophageal Squamous Cell Carcinoma or Head and Neck Squamous Cell Carcinoma
100 Clinical Results associated with KK-2260
Login to view more data
100 Translational Medicine associated with KK-2260
Login to view more data
100 Patents (Medical) associated with KK-2260
Login to view more data
100 Deals associated with KK-2260
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Phase 1 | Japan | 01 Nov 2023 | |
| Metastatic Esophageal Carcinoma | Phase 1 | Japan | 01 Nov 2023 | |
| Metastatic Solid Tumor | Phase 1 | Japan | 01 Nov 2023 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | Japan | 01 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free